InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.082

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$25 Noxopharm Announces Leadership Transition 5 Jan 2022 8:51AM $0.410 $0.082 fallen by 80%
$25 Noxopharm DARRT-2 Cancer Trial Update 14 Dec 2021 9:52AM $0.365 $0.082 fallen by 77.53%
$25 Notification of cessation of securities - NOX 2 Dec 2021 4:35PM $0.440 $0.082 fallen by 81.36%
$25 Change of Director's Interest Notice - GK 2 Dec 2021 4:30PM $0.440 $0.082 fallen by 81.36%
$25 Noxopharm Annual General Meeting Results 17 Nov 2021 3:09PM $0.460 $0.082 fallen by 82.17%
$25 Licencing Deal Expands Noxopharm Drug Opportunities 17 Nov 2021 9:20AM $0.485 $0.082 fallen by 83.09%
$25 Noxopharm 2021 AGM Corporate Presentation 17 Nov 2021 9:05AM $0.485 $0.082 fallen by 83.09%
$25 Noxopharm 2021 AGM Chairmans Address 17 Nov 2021 8:57AM $0.485 $0.082 fallen by 83.09%
$25 Retraction of Grant Announcement 16 Nov 2021 3:18PM $0.485 $0.082 fallen by 83.09%
$25 Trading Halt 15 Nov 2021 9:49AM $0.485 $0.082 fallen by 83.09%
$25 Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial 15 Nov 2021 9:10AM $0.485 $0.082 fallen by 83.09%
$25 DARRT-2 Trial Commences in the U.S. 4 Nov 2021 8:33AM $0.500 $0.082 fallen by 83.60%
$25 Unlisted Options Expiring on 30 November 2021 29 Oct 2021 2:10PM $0.525 $0.082 fallen by 84.38%
$25 Veyonda and Opdivo IONIC Study First Patient Dosed 26 Oct 2021 8:34AM $0.550 $0.082 fallen by 85.09%
$25 Patent Granted for Veyonda and Low Dose Chemotherapy 25 Oct 2021 10:57AM $0.530 $0.082 fallen by 84.53%
$25 Jobkeeper s323DB Notice 20 Oct 2021 4:15PM $0.530 $0.082 fallen by 84.53%
$25 2021 AGM Notice of Meeting and Proxy 15 Oct 2021 8:26AM $0.565 $0.082 fallen by 85.49%
$25 2021 AGM Letter to Shareholders and Proxy 15 Oct 2021 8:19AM $0.565 $0.082 fallen by 85.49%
$25 September 2021 Quarterly Activities Report and Appendix 4C 14 Oct 2021 9:23AM $0.565 $0.082 fallen by 85.49%
$25 Cleansing Notice 29 Sep 2021 6:29PM $0.565 $0.082 fallen by 85.49%
$25 Application for quotation of securities - NOX 29 Sep 2021 6:26PM $0.565 $0.082 fallen by 85.49%
$25 Veyonda Achieves Important U.S. Patent Claims 27 Sep 2021 9:56AM $0.565 $0.082 fallen by 85.49%
$25 Noxopharm 2021 Annual Report 10 Sep 2021 9:47AM $0.510 $0.082 fallen by 83.92%
$25 Noxopharm Updated Corporate Presentation 9 Sep 2021 8:58AM $0.530 $0.082 fallen by 84.53%
$25 Change of Registered Office and Principal Place of Business 30 Aug 2021 1:52PM $0.550 $0.082 fallen by 85.09%

201 - 225 of 794 results

Page 9 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.